Quanterix

The Simoa® Cytokine 4-Plex Advantage PLUS Assays deliver sensitivity down to fg/mL levels, reliably measuring low- abundance cytokines at baseline in healthy individuals and capturing subtle yet critical signals early in biological and pathological processes. Learn more: https://bit.ly/3C4XHYI #cytokines #research #biomarkers

#News: We are excited to announce our acquisition of Akoya Biosciences, Inc. The transaction will create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. This is an important step forward for our mission of early disease detection and will accelerate scientific discoveries and improve patient outcomes. Read more information and cautionary statements here: https://lnkd.in/eyYkVF9t

As more novel treatments are approved for Alzheimer’s disease, eligibility for these therapies remains an important question. New research published in Nature Aging shows the power that plasma biomarkers like p-tau217 may have on streamlining the diagnostic journey for specific groups of patients. Study author Nicholas Ashton joined our CEO Masoud Toloue to answer key questions NeurologyLive had on the new research and potential for plasma biomarkers. Read more: https://lnkd.in/eiM4Mnzy #news #neurology #biomarkers

We've launched our brand new newsletter! Twice a month we'll be sharing news from the industry, publications, and more. Subscribe here: https://bit.ly/40mXBow #newsletter #news

#News A new article in eBioMedicine – The Lancet Discovery Science by Nicholas Ashton and Henrik Zetterberg looks at the 10-year history of blood biomarker testing for Alzheimer's Disease and the groundbreaking transformation. 🚀 Thanks to innovative technologies like Simoa, blood biomarkers such as p-tau217, Aβ42/Aβ40, and NfL are changing the game in research, diagnostics and monitoring. Read more: https://lnkd.in/epFsW2en #Alzheimers #bloodbasedbiomarkers #research

Headed to #HAI2025? We look forward to kicking off the year exploring the latest developments in amyloid imaging and their implications for understanding and treating neurodegenerative diseases. Our Chief Scientific Officer, Mark T. Roskey, Ph.D., will be in attendance and is available for meetings. Book time here: https://bit.ly/3BWucIp #conference #dementia #biomarkers

#News: We are pleased to announce that David R. Walt, co-inventor of our Simoa® Technology, has received the National Medal of Technology and Innovation, bestowed by the President of the United States. David is pictured here with Arati Prabhakar, Presidential Science Advisor. Read more here: https://bit.ly/4h3xE2C #inventor #simoa #award

#QReview: With a focus on BD-tau, P-Tau217, and Nfl, this study evaluated the potential of these plasma biomarkers for diagnosing acute ischemic stroke (AIS) and predicting its severity. Read more about the findings which suggest BD-tau could serve as a valuable non-invasive tool to complement imaging in acute stroke care. https://bit.ly/40tUjjz #stroke #biomarkers #research

In a matter of days, you can develop custom immunoassays with ultrasensitivity. The Quanterix Homebrew Assay Kit and your proprietary reagents work together for rapid Simoa® assay prototyping with improved biomarker detection and ease-of-use compared to standard ELISA. Learn more: https://bit.ly/4guU2lL

The ability to detect neurological biomarkers at ultra-low levels, which have traditionally only been detectable in cerebrospinal fluid, has the potential to transform the way brain injuries and diseases are diagnosed. Simoa® is not just a better way to detect CNS biomarkers, it's...